

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM542359

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
NOVELION THERAPEUTICS INC.	FORMERLY QLT, INC.	09/24/2019	Corporation: BRITISH COLUMBIA
RECEIVING PARTY DATA			
Name:	AEGERION PHARMACEUTICALS, INC.		
Street Address:	One Main Street, Suite 800		
City:	Cambridge		
State/Country:	NEW YORK		
Postal Code:	02142		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 14			
Property Type	Number	Word Mark	
Serial Number:	87177217	NOVELION THERAPEUTICS	
Serial Number:	87177235	NOVELION THERAPEUTICS	
Registration Number:	5381517	NOVELION THERAPEUTICS	
Registration Number:	5381456	NOVELION THERAPEUTICS	
Registration Number:	5237690	BYMYSIDE	
Registration Number:	5237691	BYMYSIDE	
Registration Number:	5276666	LOWER	
Registration Number:	4607022	MYALEPT	
Registration Number:	4512713	JUXTAPID	
Registration Number:	4508190	JUXTAPID	
Registration Number:	4589120	MYALEPT	
Registration Number:	3977343	AEGERION PHARMACEUTICALS	
Registration Number:	3300046	AEGERION	
Registration Number:	3448427	AEGERION PHARMACEUTICALS, INC.	
CORRESPONDENCE DATA			
Fax Number:	6465584180		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			

OP \$365.00 87177217

Phone: 2124597115
Email: TRoot@goodwinlaw.com
Correspondent Name: Troy Root
Address Line 1: 620 8th Avenue
Address Line 4: New York, NEW YORK 10018

ATTORNEY DOCKET NUMBER: 136665-277798

NAME OF SUBMITTER: Troy Root

SIGNATURE: /s/ Troy Root

DATE SIGNED: 09/24/2019

Total Attachments: 5

source=Aegerion Restructuring -- Novelion Release of Trademarks [Execution]#page1.tif

source=Aegerion Restructuring -- Novelion Release of Trademarks [Execution]#page2.tif

source=Aegerion Restructuring -- Novelion Release of Trademarks [Execution]#page3.tif

source=Aegerion Restructuring -- Novelion Release of Trademarks [Execution]#page4.tif

source=Aegerion Restructuring -- Novelion Release of Trademarks [Execution]#page5.tif

TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS

This TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS (the "Release") is made this 24th day of September, 2019 (the "Release Date") by **NOVELION THERAPEUTICS INC.**, a corporation incorporated under the laws of British Columbia, as Lender (the "Lender"), for the benefit of **AEGERION PHARMACEUTICALS, INC.**, a Delaware corporation (the "Grantor"), with its principal place of Business located at One Main Street, Suite 800, Cambridge, Massachusetts 02142.

WHEREAS, the Grantor has entered into that certain Trademark Security Agreement, dated as of March 29, 2018 with Lender (as at any time prior to the date hereof amended, supplemented or otherwise modified, the "Security Agreement"), pursuant to which Grantor granted to Lender a continuing security interest in all right, title or interest in, to or under all of the following assets, licenses or other rights whether now or at any time hereafter owned or acquired by, or arising in favor of, such Grantor (collectively, the "Trademark Collateral"):

- A. all Trademarks, including, without limitation, those listed on Schedule I thereto;
- B. all goodwill associated with or symbolized by the Trademarks identified in clause (A) above;
- C. all assets, rights and interests that uniquely reflect or embody the Trademarks identified in clause (A) above;
- D. any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligations, to sue and collect damages for said use or infringement of any Trademark identified in clause (A) above;
- E. all amendments, renewals and extensions of any of the foregoing; and
- F. all proceeds of and rights associated with the foregoing (the "Marks");

WHEREAS, Lender has recorded with the United States Patent and Trademark Office (the "USPTO"), at Reel 6308, Frame 0858, notices of security interests in the Marks; and

WHEREAS, all outstanding amounts owed under any financing documents executed in connection with the Security Agreement have been satisfied and the Grantor has requested that Lender release its security interest in the Marks.

NOW THEREFORE, in consideration thereof and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Lender agrees as follows:

1. Release of Security Interest. Effective as of the Release Date, Lender hereby irrevocably and forever terminates, releases and discharges any and all security interests in the Marks granted by the Grantor under the Security Agreement.

2. Recordation of Release. Lender understands and agrees that this Release may be recorded by or for the Grantor with the USPTO.


3. Further Actions. Lender further agrees to execute any other documents and take any further action reasonably necessary in any state, country or jurisdiction that the Grantor may reasonably require to effect the intent and purpose of this Release, provided that all such documents are to be prepared by counsel to the Grantor and the cost and expense of such documents and actions shall be borne solely by the Grantor.

4. Capitalized Terms. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Security Agreement, as applicable.

[Signature page follows]

IN WITNESS WHEREOF, Lender has caused this Release to be executed as an instrument under seal by its duly authorized officer as of the Release Date.










NOVELION THERAPEUTICS INC.
as Lender






By: 
Name: Ben Harshbarger
Title: Interim Chief Executive Officer and
General Counsel

[Signature Page to Termination and Release of Security Interest in Trademarks]

TRADEMARK
REEL: 006753 FRAME: 0720

**SCHEDULE I
TRADEMARKS**

Trademark	Image	Source	Application Number	Registration Number	Application Date	Registration Date	Owner Name
NOVELLON THERAPEUTICS		US	87177217		20-SEP-2016		Aegerion Pharmaceuticals, Inc.
NOVELLON THERAPEUTICS		US	87177235		20-SEP-2016		Aegerion Pharmaceuticals, Inc.
NOVELLON THERAPEUTICS		US	87072521	5381517	15-JUN-2016	16-JAN-2018	Aegerion Pharmaceuticals, Inc.
NOVELLON THERAPEUTICS		US	87043469	5381456	19-MAY-2016	16-JAN-2018	Aegerion Pharmaceuticals, Inc.
BYMYSIDE		US	86786368	5237690	13-OCT-2015	04-JUL-2017	Aegerion Pharmaceuticals, Inc.
BYMYSIDE		US	86786387	5237691	13-OCT-2015	04-JUL-2017	Aegerion Pharmaceuticals, Inc.
LOWER		US	86235722	5276666	28-MAR-2014	29-AUG-2017	Aegerion Pharmaceuticals, Inc.
MYALEPT		US	86043958	4607022	21-AUG-2013	16-SEP-2014	Aegerion Pharmaceuticals, Inc.
JUXTAPID		US	85981114	4512713	22-FEB-2013	08-APR-2014	Aegerion Pharmaceuticals, Inc.

JUXTAPID		US	85980934	4508190	14-DEC-2012	01-APR-2014	Aegerion Pharmaceuticals, Inc.
MYALEPT		US	85484675	4589120	01-DEC-2011	19-AUG-2014	Aegerion Pharmaceuticals, Inc.
AEGERION PHARMACEUTIC ALS		US	85162494	3977343	27-OCT-2010	14-JUN-2011	Aegerion Pharmaceuticals, Inc.
AEGERION		US	78906083	3300046	12-JUN-2006	25-SEP-2007	Aegerion Pharmaceuticals, Inc.
AEGERION PHARMACEUTIC ALS, INC. (& SMOOSH DESIGN)		US	77283527	3448427	19-SEP-2007	17-JUN-2008	Aegerion Pharmaceuticals, Inc.

TRADEMARK

REEL: 006753 FRAME: 0722

RECORDED: 09/24/2019